Download Image
    
Share
  
Post
Ravulizumab for COVID-19
2 studies with 481 patients
Hospital Icon Control
Hospital Icon Ravulizumab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Ravulizumab studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -5% Mortality -5% RCTs -5% RCT mortality -5% Late -5% Favorsravulizumab Favorscontrol
Dec 31
2023
 Hall et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(23)00376-4 Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
1% lower mortality (p=0.98), 53% higher progression (p=0.13), 24% higher need for oxygen therapy (p=0.57), and 3% lower hospital discharge (p=0.86). RCT 417 hospitalized COVID-19 patients in the UK showing no significant difference in a composite primary endpoint (time to death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or rena..
Mar 20
2023
 Annane et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(23)00082-6 Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
8% higher mortality (p=0.76). RCT 201 mechanically ventilated patients with severe COVID-19 showing no significant difference in mortality with ravulizumab. The study was terminated early due to futility.